EU regulators to review bluebird’s gene therapy LentiGlobin
The European Medicines Agency will undertake an accelerated review of bluebird bio’s LentiGlobin, a gene therapy for the treatment of transfusion-dependent beta-thalassemia.
Read More
Tag: TDBT
PRIME status for Orchard’s gene therapy
The European Medicines Agency has granted Orchard Therapeutics’ experimental gene therapy OTL-300 PRIME designation as a potential treatment for the most severe form of beta-thalassemia.
Read More
- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
